Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease (NCT06451419) | Clinical Trial Compass
By InvitationNot Applicable
Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease
Spain40 participantsStarted 2024-07-01
Plain-language summary
The goal of this observational study is to describe non motor symptoms in a prospective study of patients with Parkinson's disease associated to glucocerebrosidase (GBA-PD) mutations.
The main questions it aims to answer are:
* Do GBA-PD patients have a greater burden of non motor symptoms?
* How do these non motor symptoms evolve during a prospective follow up of two years?
* Are these non motor symptoms different from those that affect Parkinson's disease patients without glucocerebrosidase mutations (non GBA-PD), in prevalence, severity and type?
* Do these non motor symptoms correlate with objective measures such as posturography or speed reaction tests?
* Is there a test or combination of tests that can predict the appearance of early or severe non motor symptoms?
For this reason researchers will compare the GBA-PD group of patients with a group of non mutated GBA Parkinson disease.
Participants will undergo a neurological and neuropsychological evaluation with different tests in subsequent visits for a total of 2 years.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged over 18 years old.
* Fulfill Parkinson's disease criteria of Movement Disorder Society 2015.
* Parkinson's disease symptoms began before they were 70 and/or Parkinson's disease family history.
* Underwent a genetic test of Parkinson's disease related genes.
* Heterozygous mutation of glucocerebrosidase gene (only cases).
* Absence of mutation in the Parkinson's disease genetic test (only controls).
Exclusion Criteria:
* Suspicion of atypical parkinsonism.
* Personal history of other neurodegenerative disorders such as Alzheimer's disease.
* Personal history of significant cerebrovascular damage, intracraneal lessions or important craneoencephalic trauma.
* Deep brain stimulation treatment for Parkinson's disease.
* Moderate or severe dementia that precludes from performing the tests.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in non motor symptoms scale from baseline to 2 years
Timeframe: 2 years
2
Change in non motor symptoms scale from baseline to 6 months
Timeframe: 6 months
3
Change in non motor symptoms scale from 6 months to 1 year
Timeframe: 6 months
4
Change in non motor symptoms scale from 12 months to 18 months
Timeframe: 6 months
5
Change in non motor symptoms scale from 18 months to 24 months